曹娟 李平

*基金项目：宜春市科技计划项目（2023ZDJH2772）

【摘要】 目的：探究纤溶酶注射液联合注射用曲克芦丁治疗急性脑梗死（ACI）的效果。方法：选取宜春市第二人民医院2022年1月—2023年8月收治的70例ACI患者为研究对象，采用随机数字表法将其分为对照组和观察组，每组35例。所有患者均给予吲哚布芬和硫酸氢氯吡格雷抗血小板，阿托伐他汀稳定斑块治疗。对照组给予曲克芦丁治疗，观察组给予纤溶酶注射液联合曲克芦丁治疗。比较两组临床疗效、神经功能、炎症因子指标及不良反应发生情况。结果：观察组总有效率显著高于对照组，差异有统计学意义（P<0.05）。两组治疗前、治疗1、7、10 d的美国国立卫生研究院卒中量表（NIHSS）评分组间、时间及交互效应比较，差异均有统计学意义（P<0.05）；治疗1、7、10 d后，两组NIHSS评分较治疗前均降低，且观察组NHISS评分均显著低于对照组（P<0.05）。治疗后，两组白细胞介素-6（IL-6）、白细胞介素-8（IL-8）及超敏C反应蛋白（hs-CRP）均较治疗前降低，且观察组IL-6、IL-8及hs-CRP水平均显著低于对照组（P<0.05）。两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论：采用纤溶酶注射液联合注射用曲克芦丁治疗ACI效果显著，对患者神经功能、炎症反应均有改善作用，同时不良反应发生较少。

【关键词】 急性脑梗死 纤溶酶 曲克芦丁 神经功能 炎症因子 不良反应

Effect of Fibrinogenase Injection Combined with Troxerutin for Injection in the Treatment of Acute Cerebral Infarction/CAO Juan， LI Ping. //Medical Innovation of China， 2024， 21（13）： 0-028

[Abstract] Objective： To investigate the effect of Fibrinogenase Injection combined with Troxerutin for Injection in the treatment of acute cerebral infarction （ACI）. Method： A total of 70 patients with ACI who were admitted to Yichun Second People's Hospital from January 2022 to August 2023 were selected as the study subjects， were divided into control group and observation group by random number table method， with 35 cases in each group. All patients were given Indobufen and Clopidogrel Bisulfate antiplatelet therapy and Atorvastatin treatment for stabilizing plaque. On this basis， the control group was treated with Troxerutin， the observation group was treated with Fibrinogenase Injection combined with Troxerutin. Clinical efficacy， neurological function， inflammatory factors and incidence of adverse reactions in the two groups were compared. Result： The total effective rate of the observation group was significantly higher than that of the control group， the difference was statistically significant （P<0.05）. There were statistically significant differences in the national institutes of health stroke scale （NIHSS） scores of the two groups before treatment and after 1， 7 and 10 d of treatment in terms of inter-group， time and interaction effect （P<0.05）; after 1， 7 and 10 d of treatment， the NIHSS scores of both groups were decreased compared to those before treatment， and the NHISS scores of the observation group were significantly lower than those of the control group （P<0.05）. After treatment， the levels of interleukin-6 （IL-6）， interleukin-8 （IL-8） and hypersensitive C reactive protein （hs-CRP） in both groups were decreased compared to those before treatment， and the levels of IL-6， IL-8， and hs-CRP in the observation group were significantly lower than those in the control group， the differences were statistically significant （P<0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups （P>0.05）. Conclusion： The combined treatment of Fibrinogenase Injection and Troxerutin for Injection can achieve significant therapeutic effect on ACI as it can significantly improve the patients' neurological function and inflammatory response， with a low incidence of adverse reactions.

[Key words] Acute cerebral infarction Fibrinogenase Troxerutin Neurological function Inflammatory factor Adverse reaction

First-author's address： Department of Neurology， Yichun Second People's Hospital， Yichun 336000， China

doi：10.3969/j.issn.1674-4985.2024.13.006

脑卒中为临床常见的脑血管疾病，临床上脑卒中患者多为缺血性脑卒中[1]。缺血性脑卒中又称脑梗死，主要由于患者脑动脉硬化或形成血栓，导致动脉血管狭窄或堵塞，进而引起局部脑组织缺血缺氧，使患者神经受损[2]。其中急性脑梗死（ACI）具有较高的致残、致死率，对患者的生命安全具有严重威胁。而由于ACI好发于中老年人群，此类人群常伴有其他基础疾病，具有更高的危险性[3]。研究显示，对ACI的及时治疗可显著改善患者症状，恢复患者神经功能[4]。因此为改善ACI患者预后，寻找科学有效的药物对ACI患者进行治疗具有重要意义。……